Melanoma the new perspectives from clinical and translational researchOccelli, Marcella; Vandone, Anna M.; Cauchi, Carolina; Merlano, Marco C.Anti-Cancer Drugs: July 2019 - Volume 30 - Issue 6 - p 543–553 doi: 10.1097/CAD.0000000000000798 REVIEW ARTICLES Buy Abstract Author InformationAuthors Article MetricsMetrics The prognosis of metastatic melanoma has not changed throughout the 20th century. However, in the last decade, we have witnessed a continuous improvement in survival, with many long-term survivors. These results are largely because of the simultaneous development of the knowledge in the biology of metastatic malignant melanoma and of the relationship between the disease and the host’s immune system that allowed the development of effective new treatments. In this overview, we summarize the therapies available today, their biological rationale, and the research field currently under investigation divided into three main chapters: target therapies, immunotherapies, and their combination. Department of Medicine, Clinical Oncology and Translational Research, Azienda Ospedaliera Santa Croce and Carle University Teaching Hospital, Cuneo, Italy Correspondence to Marcella Occelli, MD, Department Of Medicine, Clinical Oncology and Translational Research, Azienda Ospedaliera Santa Croce and Carle University Teaching Hospital, Via Michele Coppino 26, 12100 Cuneo, Italy Tel: +39 017 161 6350; fax: +39 017 161 6360; e-mail: email@example.com Received November 29, 2018 Accepted April 4, 2019 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.